Bicycle Therapeutics plc
| NASDAQ: BCYC | Healthcare / Biotechnology / United Kingdom |
| 28.38 | -3.90 | -12.08% | Vol 488.24K | 1Y Perf 101.03% |
| Apr 9th, 2021 16:00 DELAYED |
| BID | 28.45 | ASK | 37.00 | ||
| Open | 32.23 | Previous Close | 32.28 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 35.57 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 25.33 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★ 52.33 | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Market Cap | 655.29M | Earnings Rating | Strong Sell | |
| Price Range Ratio 52W % | 76.67 | Earnings Date | 6th May 2021 |
Today's Price Range 28.2833.20 | 52W Range 12.5433.20 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -6.89% | ||
| 1 Month | 3.77% | ||
| 3 Months | 44.35% | ||
| 6 Months | 49.29% | ||
| 1 Year | 101.03% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -51.81 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -36.29 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -34.89 | |||
Return on invested Capital Q | -14.76 | |||
Return on invested Capital Y | -49.66 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 0.80 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -11.20 | ||||
| 7.23 | ||||
| 76.15 | ||||
| - | ||||
| -17.30 | ||||
| -0.93 | ||||
| 7.23 | ||||
| 4.13 | ||||
| 583.58M | ||||
| Forward PE | -8.73 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.50 | ||||
| 6.70 | ||||
| 0.14 | ||||
| 0.17 | ||||
| -112.20 | ||||
| Leverage Ratio | 1.70 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -335.50 | ||||
| -325.20 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 9.26M | ||||
| 0.40 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.50 | -0.83 | -66.00 |
| Q03 2020 | -0.66 | -0.52 | 21.21 |
| Q02 2020 | -0.55 | -0.67 | -21.82 |
| Q01 2020 | -0.02 | -0.63 | -3 050.00 |
| Q04 2019 | -0.54 | -0.25 | 53.70 |
| Q03 2019 | -0.55 | -0.53 | 3.64 |
| Q02 2019 | -0.53 | -1.40 | -164.15 |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.66 | -13.79 | Negative |
| 6/2021 QR | -0.71 | -14.52 | Negative |
| 12/2021 FY | -2.99 | -20.08 | Negative |
| 12/2022 FY | -3.49 | -31.20 | Negative |
| Next Report Date | 6th May 2021 |
| Estimated EPS Next Report | -0.66 |
| Estimates Count | 5 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 488.24K |
| Shares Outstanding | 23.09M |
| Trades Count | 2.51K |
| Dollar Volume | 4.50M |
| Avg. Volume | 185.51K |
| Avg. Weekly Volume | 315.31K |
| Avg. Monthly Volume | 212.04K |
| Avg. Quarterly Volume | 195.11K |
Bicycle Therapeutics plc (NASDAQ: BCYC) stock closed at 28.38 per share at the end of the most recent trading day (a -12.08% change compared to the prior day closing price) with a volume of 488.28K shares and market capitalization of 655.29M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 81 people. Bicycle Therapeutics plc CEO is Kevin Lee.
The one-year performance of Bicycle Therapeutics plc stock is 101.03%, while year-to-date (YTD) performance is 58.11%. BCYC stock has a five-year performance of %. Its 52-week range is between 12.54 and 33.2, which gives BCYC stock a 52-week price range ratio of 76.67%
Bicycle Therapeutics plc currently has a PE ratio of -11.20, a price-to-book (PB) ratio of 7.23, a price-to-sale (PS) ratio of 76.15, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -36.29%, a ROC of -34.89% and a ROE of -51.81%. The company’s profit margin is -%, its EBITDA margin is -325.20%, and its revenue ttm is $9.26 Million , which makes it $0.40 revenue per share.
Of the last four earnings reports from Bicycle Therapeutics plc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.66 for the next earnings report. Bicycle Therapeutics plc’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Bicycle Therapeutics plc is Strong Buy (1), with a target price of $35.57, which is +25.33% compared to the current price. The earnings rating for Bicycle Therapeutics plc stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bicycle Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Bicycle Therapeutics plc has a Buy technical analysis rating based on Technical Indicators (ADX : 11.69, ATR14 : 2.58, CCI20 : -41.24, Chaikin Money Flow : 0.22, MACD : -0.50, Money Flow Index : 73.09, ROC : 0.95, RSI : 50.68, STOCH (14,3) : 63.42, STOCH RSI : 1.00, UO : 49.23, Williams %R : -36.58), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bicycle Therapeutics plc in the last 12-months were: Greg Winter (Option Excercise at a value of $0), Kevin Lee (Sold 16 285 shares of value $447 220 ), Nicholas Keen (Sold 10 000 shares of value $284 843 ), Pierre Legault (Option Excercise at a value of $88 522), Pierre Legault (Sold 10 000 shares of value $290 000 )
Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.
CEO: Kevin Lee
Telephone: +44 1223261503
Address: B900, Babraham Research Campus, Cambridge CB22 3AT, , GB
Number of employees: 81
